| Adam H. Schechter |
President and CEO, Director |
$25.2 M |
|
|
Mar 27, 2024 |
| Glenn A. Eisenberg |
Chief Financial Officer, EVP |
$10.5 M |
-$7.45 M |
-41.5% |
Apr 30, 2024 |
| Brian J. Caveney |
EVP, Pres of ED, CMO & CSO |
$6.85 M |
|
|
Mar 27, 2024 |
| Lance Berberian |
Evp, Cio & Cto |
$6.52 M |
|
|
Mar 27, 2024 |
| Jean Luc Belingard |
Director |
$4.03 M |
|
|
Feb 6, 2024 |
| Thomas Pike |
Pres & CEO Clinical Business |
$3.57 M |
|
|
Jan 9, 2023 |
| KerrII B. Anderson |
Director |
$3.41 M |
-$1.16 M |
-25.4% |
Apr 30, 2024 |
| Peter M. Neupert |
Director |
$2.88 M |
|
|
Feb 6, 2024 |
| Garheng Kong |
Director |
$2.87 M |
|
|
Feb 6, 2024 |
| Paul R. Kirchgraber |
CEO, Covance Drug Development |
$2.84 M |
|
|
May 19, 2023 |
| Dwight Gary Gilliland |
Director |
$2.16 M |
|
|
Feb 6, 2024 |
| Richelle P. Parham |
Director |
$2.12 M |
|
|
Feb 6, 2024 |
| Mark S. Schroeder |
EVP, Pres Diagnostics & COO |
$1.98 M |
-$2.51 M |
-55.9% |
Apr 1, 2024 |
| R. Sanders Williams |
Director |
$1.87 M |
|
|
Feb 6, 2024 |
| Sandra D. van der Vaart |
EVP, Chief Legal Officer |
$1.66 M |
-$1.35 M |
-44.7% |
May 14, 2024 |
| Jonathan P. DiVincenzo |
EVP, Pres, Central Labs & Intl |
$1.61 M |
-$108 K |
-6.27% |
Mar 27, 2024 |
| Megan D. Bailey |
EVP, Chief Strategy Officer |
$1.28 M |
|
|
Apr 1, 2024 |
| Amy B. Summy |
EVP, Chief Marketing Officer |
$1.15 M |
-$810 K |
-41.3% |
Apr 1, 2024 |
| Jeffrey A. Davis |
Director |
$1.02 M |
|
|
Feb 6, 2024 |
| Judith C. Seltz |
Evp, Chro |
$918 K |
|
|
Mar 30, 2023 |
| Kathryn E. Wengel |
Director |
$724 K |
|
|
Feb 6, 2024 |
| Peter J. Wilkinson |
SVP, Chief Accounting Officer |
$598 K |
-$790 K |
-56.9% |
Apr 29, 2024 |
| Kirsten M. Kliphouse |
Director |
$506 K |
|
|
Feb 6, 2024 |
| Anita Z. Graham |
Evp, Chro |
$449 K |
|
|
Feb 6, 2024 |
| Paul Rothman |
Director |
$350 K |
|
|
Jun 6, 2024 |